Synthesis, In Silico Studies, and In Vitro Anti-Inflammatory Activity of Novel Imidazole Derivatives Targeting p38 MAP Kinase.

A series of eight novel -substituted [4-(trifluoro methyl)-1-imidazole-1-yl] amide derivatives () were synthesized, characterized, and evaluated for their in vitro p38 MAP kinase anti-inflammatory inhibitory activity. The synthesized compounds were obtained by coupling [4-(trifluoromethyl)-1-imidazole-1-yl] acetic acid with 2-amino--(Substituted)-3-phenylpropanamide derivatives utilizing 1-[bis(dimethylamino)methylene]-1-1,2,3-triazolo[4,5-] pyridinium 3-oxide hexafluorophosphate as a coupling agent. Various spectroscopic methods established and confirmed their structures, specifically, H NMR, C NMR, Fourier transform infrared (FTIR), and mass spectrometry. In order to emphasize the binding site of the p38 MAP kinase protein and newly synthesized compounds, molecular docking studies were carried out. In the series, compound had the highest docking score of 7.83 kcal/mol. The ADME studies were performed using web software. Studies revealed that all the synthesized compounds were orally active and showed good gastrointestinal absorption within the acceptable range. Lipinski's "rule of five" was used to determine drug-likeness. The synthesized compounds were screened for their anti-inflammatory activity by performing an albumin denaturation assay in which five compounds (, , , , and ) were found to exhibit substantial activity. Hence, these were further selected and proceeded for the evaluation of p38 MAP kinase inhibitory activity. The compound possesses considerable p38 kinase inhibitory anti-inflammatory activity with an IC value of 403.57 ± 6.35 nM compared to the prototype drug adezmapimod (SB203580) with an IC value of 222.44 ± 5.98 nM. Some further structural modifications in compound could contribute to the development of new p38 MAP kinase inhibitors with an improved IC value.